MDT participation is a central, expected strand of every oncology Portfolio Pathway application. The evidence that carries weight is not an attendance log - it is annotated case-level records showing your clinical decision-making at the MDT: cases you presented, decisions you shaped, and treatment plans you led. Both RCR (Clinical Oncology) and JRCPTB (Medical Oncology) assessors look for this evidence mapped to the GMC's four domains.
Why MDT evidence matters in oncology applications
The cancer MDT is the structural centre of NHS oncology practice. Under NHS England guidance, every new cancer diagnosis must be discussed at a multidisciplinary team meeting before treatment commences, and ongoing complex cases are expected to return to the MDT at decision points. This is not a voluntary professional norm - it is a quality standard embedded in NHS cancer service specifications, and it makes the MDT the primary arena in which consultant-level oncology decision-making occurs in the NHS.
For a Portfolio Pathway application in either Clinical Oncology or Medical Oncology, this has a direct implication: the MDT is where the most consequential clinical decisions are made, and therefore where the most consequential evidence is generated. A portfolio that omits MDT evidence, or presents only an attendance log, leaves the assessor without visibility of what is arguably the defining context of NHS oncology Consultant work.
The GMC's four-domain framework maps naturally onto MDT participation. Domain 1 (Knowledge, Skills and Performance) is demonstrated through case presentation and treatment decision reasoning. Domain 2 (Safety and Quality) is visible in how you apply treatment protocols, escalate concerns, and handle clinical risk in a multidisciplinary context. Domain 3 (Communication, Partnership and Teamwork) is the domain MDTs most directly evidence. Domain 4 (Maintaining Trust) surfaces in the MDT through consent discussions, patient-centred decision-making, and cases where you advocated for a treatment decision that reflected the patient's expressed wishes over the statistically preferred option.
MDT participation evidence is not a substitute for WBAs, procedure logs, or audit evidence. It is a distinct and required strand that sits alongside them. The assessors' question is not "does this applicant attend MDTs?" - they assume that. The question is "can they show that their MDT contributions are at consultant level in terms of clinical reasoning, decision complexity, and leadership?"
The MDT evidence strand is one where non-substantive Consultants often have a genuine advantage over applicants from outside the NHS. If you are working in a trust-grade Consultant or specialist grade post in an oncology department, you are almost certainly attending and contributing to MDTs as a matter of clinical routine. The task is documentation, not generation.
For internationally-trained oncologists building a portfolio from outside the NHS, the challenge is more material. Tumour boards and multidisciplinary conferences exist in many healthcare systems, but the NHS MDT model - its mandatory scope, its core membership requirements, its documented decision records - is distinctive enough that direct equivalence is not assumed. The article on translating overseas evidence covers the general framework, but the oncology-specific point is that getting a UK post before applying is strongly advisable if MDT evidence will be a significant gap.
Clinical Oncology vs Medical Oncology: two different routes
Oncology is unusual in the Portfolio Pathway landscape because it covers two distinct specialties with different regulatory bodies, different curricula, and different assessment processes. Getting the pathway right matters before you start building evidence.
- Assessed by the Royal College of Radiologists (RCR)
- Dual-modality specialty: both radiotherapy and systemic anti-cancer treatment (SACT)
- Curriculum defines CiPs that include radiotherapy planning, simulation, prescribing, and SACT
- RCR Portfolio Pathway process involves panel review by senior RCR Fellows
- MDT evidence expected to show both radiotherapy planning discussions and systemic treatment decisions
- Clinical Oncology MDTs typically include both clinical and medical oncologists, radiologists, pathologists, and surgeons
- Evidence of radiotherapy target volume delineation discussions in MDT context is a specific strand
- Assessed by the JRCPTB (Joint Royal Colleges of Physicians Training Board)
- SACT-focused specialty: chemotherapy, immunotherapy, targeted therapy, endocrine therapy
- Requires MRCP(UK) Specialty Certificate Examination (SCE) in Medical Oncology alongside the portfolio
- JRCPTB assessment uses Generic and Medical Oncology Specialty Curricula
- MDT evidence expected to show systemic therapy decision-making, trial eligibility, and complex case management
- Cross-specialty MDT participation (haemato-oncology, palliative medicine interfaces) adds breadth
- Research and clinical trial integration in MDT discussions is a recognised evidence strand
Note on eligibility: If you have been practising as an oncologist in the NHS, your daily clinical work determines which pathway you sit in. Clinical Oncologists prescribe radiotherapy. Medical Oncologists do not. If you have been doing both, clarify your primary specialty with the RCR and JRCPTB before applying. Applying to the wrong body is a delay you cannot afford.
Both pathways use the GMC's four-domain framework to assess evidence, and both expect MDT participation to feature prominently. The difference is in what the MDT evidence should show: for Clinical Oncology, assessors will be looking for evidence that spans both radiotherapy and systemic therapy decisions; for Medical Oncology, the focus is primarily on systemic treatment planning, clinical complexity, and where applicable, clinical trial eligibility and enrolment decisions.
The Specialty Specific Guidance (SSG) is the document that tells you precisely what your pathway requires. For Clinical Oncology, the SSG is maintained by the RCR and links to the Clinical Oncology Curriculum. For Medical Oncology, the SSG is maintained by the JRCPTB. Read both documents from start to finish before finalising your evidence strategy, not after you have assembled the evidence.
GMC domain mapping for MDT participation
Before assembling MDT evidence, map your candidate material against the four GMC domains. This is not an abstract exercise. Different types of MDT contribution - presenting, deciding, coordinating, chairing, raising safety concerns - map to different domains, and a strong oncology portfolio demonstrates all four through MDT evidence.
Oncology MDT evidence across the four GMC domains
Evidence mapping- Complex treatment decision rationale presented at MDT
- Protocol application and deviation decisions with clinical reasoning
- Radiotherapy planning discussions (Clinical Oncology)
- Systemic therapy regimen selection with evidence-based justification
- Staging review and prognostic assessment at MDT
- Clinical trial eligibility assessment and recommendation
- Response assessment interpretation: RECIST, PET criteria
- Toxicity risk assessment before SACT initiation
- Complication recognition and MDT escalation
- Protocol deviation with documented clinical rationale
- Dose modification decisions and safety rationale
- Near-miss or safety concern raised in MDT forum
- SACT prescribing governance and MDT sign-off
- MDT coordination to prevent care gaps in complex cases
- MDT chairing or coordination with documented outcomes
- Cross-specialty communication: surgical, radiological, pathological input integrated
- Patient's expressed preferences represented in MDT discussion
- Palliative care interface discussion at MDT
- Communication of complex MDT decision to patient after meeting
- Clinical nurse specialist and allied health team coordination
- MDT referral letters and outcome communications
- Patient-centred decision when treatment consensus differed from patient's wish
- Capacity assessment discussion at MDT
- Advance care planning brought into MDT by you
- Handling of treatment refusal with ethical rationale documented
- Escalation of concerns about care standards within MDT
- Research consent discussions referenced in MDT context
Most MDT evidence will lead with Domains 1 and 3 - that is the nature of MDT work. The additional value of mapping is that it makes Domains 2 and 4 visible. If your MDT log only covers Domains 1 and 3, there is an implicit signal to assessors that your practice does not engage with safety governance and professional ethics at the MDT level. That signal may be inaccurate, but an unaddressed portfolio gap is read as a clinical gap until it is explained.
Types of MDT evidence and their weight
Not all MDT evidence is equal. The range runs from an attendance log at one end - useful context, minimal evidential weight - to a detailed annotated case entry demonstrating complex decision-making at the other. The table below maps evidence types to their evidential function.
| Evidence type | What it demonstrates | Weight |
|---|---|---|
| Attendance log (dates, tumour sites, role) | Establishes that MDT participation occurred. Proves continuity. Does not demonstrate clinical contribution. | Supporting |
| MDT outcome records listing cases you presented | Shows active case presentation role. Provides case-level evidence of caseload breadth and complexity. | Moderate |
| Annotated case-level MDT entry (see mockup below) | Full Domain 1-4 mapping. Shows clinical reasoning, decision-making, patient-centred considerations. Primary evidence unit. | Primary |
| MDT chairing record with documented decision outcomes | Domain 1 leadership; Domain 3 facilitation and communication. Elevates contributor evidence to clinical leader evidence. | Primary |
| MDT coordinator role evidence | Domain 3 and Domain 2 (governance). Shows organisational leadership and service quality role beyond clinical participation. | Moderate |
| MDT-linked WBA (CbD of a case discussed at MDT) | Links WBA evidence directly to MDT context. The strongest form of MDT evidence: your assessor's judgment of your contribution, not your own account. | Primary |
| MDT outcome letter or SACT plan you authored | Shows the documentary output of your MDT contribution. Maps to Domain 1 (decision) and Domain 3 (communication). | Moderate |
| Reflection on MDT case (linked to reflective log) | Domain 4 (honest self-assessment); pairs with case-level entry to create a full three-layer evidence unit. | Moderate |
The pattern in strong portfolios is the pairing of evidence types rather than the accumulation of a single type. An annotated case entry paired with a linked CbD and a reflective note creates a three-layer evidence unit that covers all four domains and gives assessors what they need to credit the case without asking further questions. A stack of 60 attendance entries with no case-level detail does the opposite: it creates a question about why the participation appears not to have been clinically formative.
How to document MDT participation for the portfolio
The documentation approach that generates the most useful evidence is contemporaneous, systematic, and layered. The three layers are the log, the case entry, and the annotation. None of them needs to be time-consuming to produce if you build the habit early.
Keep a running MDT log
A simple spreadsheet or notes document recording each MDT you attended, the date, the tumour site, your role (presenter, contributor, chair, observer), the number of cases discussed, and the number you personally presented or significantly contributed to. This log is the skeleton on which everything else hangs. It takes two minutes to complete after each meeting if you do it the same day. It takes hours to reconstruct retrospectively from calendar entries.
Flag complex or illustrative cases in real time
Not every case needs a full annotated entry. But some cases, as they arise in the MDT, will be clinically illustrative: a novel targeted therapy decision, a complex staging case with genuine diagnostic uncertainty, a patient where you recommended a different approach to the consensus and had to articulate why. Flag these cases in your log with a note at the time. "Case 4 - unusual EGFR exon 20 insertion, non-standard regimen, need to write up" is enough to trigger the full entry later that day or week.
Write the annotated case entry promptly
The annotated case entry is the primary evidence unit (see the mockup below). Write it within a few days of the MDT while the case details are current. The entry covers: the clinical context (anonymised), the presenting problem or decision point, your contribution to the discussion, the outcome and decision reached, and the domain annotation. It should take 20 to 30 minutes per case. You do not need 50 of these - 15 to 20 high-quality annotated entries across a range of case types, decision contexts, and GMC domains will serve your portfolio far better than a larger number of thin entries.
Link to supporting documents where they exist
If an MDT case generated an outcome letter that you wrote, a SACT prescription you signed, a CbD you requested on the case, or a reflective entry you wrote, link these. The cross-referencing tells assessors that the case was not an isolated event but part of a coherent clinical practice. It also demonstrates that your MDT contributions have downstream clinical consequences - the hallmark of a participant who is doing more than attending.
Curate, do not dump
Submitting everything you have documented is rarely the right move. Before submission, review your MDT evidence set and curate it: select the cases that best demonstrate the range of your contribution (case complexity, tumour sites, decision types, domain coverage), and omit cases that duplicate rather than extend the picture. If you have 8 annotated lung cancer MDT entries and no breast, renal, or rare tumour entries, your portfolio suggests a narrow caseload - even if that is not true. Curation is part of the communication with assessors.
Chair, presenter, contributor: what the distinctions mean
MDT participation means different things depending on your role in the meeting, and those differences are evidentially significant. Being precise about your role - and documenting it accurately - is more important than overclaiming a seniority you did not have in a given meeting.
The distinction between "presented the case" and "contributed to the discussion of a case presented by a colleague" matters to assessors. Do not describe yourself as chairing an MDT you attended as a contributor, or as presenting a case that a registrar presented while you observed. Assessors can and do query clinical referees about participation levels. Overclaiming undermines your entire portfolio, not just the MDT section.
MDT chair
Chairing an MDT is one of the most direct demonstrations of Domain 1 leadership available in oncology practice. The chair is responsible for managing the meeting flow, ensuring all cases are appropriately discussed, facilitating consensus, and preventing individual cases from dominating at the expense of patient safety across the whole list. Chairing evidence should document: the frequency of your chairing role, the tumour site MDT, the typical case volume, any specific challenges you managed (contentious clinical decisions, safety concerns raised, complex cases referred elsewhere), and the administrative or governance aspects of the role if you held a standing position.
If you have chaired MDTs only occasionally - covering for an absent regular chair, or chairing specific case types - document this accurately. Occasional chairing evidence is legitimate and useful; it shows that you are capable of stepping into the leadership role, which is a Domain 1 and Domain 3 marker even if chairing is not your standing role.
Case presenter
Presenting cases at MDT is the most direct form of active contribution. Case presentation evidence should show: the range of cases you presented (tumour sites, complexity levels, treatment contexts), the types of decision the MDT reached following your presentation, and any cases where your presentation shaped or changed the treatment direction. If you routinely present a high volume of cases per meeting, note this - it establishes caseload and the scale of your decision-making responsibility. If you present complex or rare cases that you specifically selected because they needed expert MDT input, document why you brought each one: the clinical question you were seeking to answer is itself evidence of consultant-level judgement.
Clinical contributor
Contributing to the discussion of a case presented by a colleague is a legitimate and important part of MDT participation. Senior oncologists routinely contribute technical expertise - a second view on a radiotherapy plan, a perspective on an unusual systemic therapy response, a relevant clinical trial they are aware of - to cases presented by others. This contribution is evidential for Domain 1 but requires more specific documentation to carry weight, because a bare attendance log does not distinguish the active contributor from the passive attendee. Annotate the specific cases where your contribution was material, the nature of that contribution, and the outcome decision.
Building an annotated MDT case entry
The annotated MDT case entry is the unit of evidence that does the most work in your portfolio. Below is an example format that covers the key elements assessors need to credit the case against the GMC domains. The case detail should be anonymised to remove all patient identifiers before inclusion in any submission.
Date: [month/year] - Anonymised per portfolio guidelines. Regular weekly meeting. Approximate attendance: 12 clinicians.
Domain 1: Biomarker-driven treatment personalisation, protocol deviation rationale, staging interpretation, clinical trial knowledge applied to treatment decision. Domain 2: Timing decision balanced against surgical risk; delay safety formally confirmed with surgeon. Domain 3: Cross-specialty consensus building; trial enrolment requiring specialist nurse and research team coordination. Domain 4: Trial enrolment consent implications; patient informed of delay and rationale in post-MDT consultation (clinic letter attached as linked document).
The format above can be adapted to any tumour site or decision type. The key elements are: the decision question that you brought to the MDT, your specific contribution to the discussion, the outcome reached, and the domain annotation. The annotation is not a formality - it is the analytical layer that makes the clinical record an evidence entry. Without it, assessors are left to do the interpretation themselves, and busy assessors tend to undervalue evidence they have to work to interpret.
How much is enough
Neither the RCR nor the JRCPTB specifies a mandatory MDT attendance count or case entry number. The expectation is more holistic: the evidence should demonstrate regular, sustained, active participation over a representative period, and should give assessors sufficient material to assess your capabilities against the relevant CiPs.
Working from what assessors across both pathways report as a reasonable evidence base, the following provides a practical orientation. These are not thresholds you can tick off - they are the shape of a portfolio that assessors do not return with gaps queries.
If your clinical post involves lower MDT frequency than the above implies - for example a locum post with limited regular MDT access, or a post in a smaller unit with less structured MDT arrangements - discuss this with your educational supervisor early. The evidence requirement does not disappear because your post structure makes it harder to generate; but there are documented ways to supplement through case conferences, virtual tumour boards, or structured case review meetings that the assessors will accept if properly contextualised.
Pairing MDT evidence with other evidence types
MDT evidence is most powerful when it functions as part of a coherent evidence cluster rather than standing alone. The three most productive pairings are with WBAs, with reflective entries, and with clinic letters.
MDT case + WBA
A Case-based Discussion (CbD) conducted on a case you presented at MDT is the most direct form of assessor-validated MDT evidence. The WBA gives your educational supervisor or assessor the context of the MDT decision, your contribution to it, and the opportunity to probe your clinical reasoning in the same way they would for any other CbD case. For MSF purposes, MDT colleagues who observed your chairing or presentation role can be valuable raters - they have direct, specific, clinical-context feedback to give, rather than generic professional impressions.
MDT case + reflective entry
A reflective entry linked to an MDT case entry creates a two-layer evidence unit that covers Domains 1, 3, and 4 comprehensively. The MDT entry documents what happened; the reflection documents what you learned, what you would do differently, and how the case informs your ongoing practice. Cases where the MDT reached a decision you initially disagreed with, or where a case you presented triggered a change in your clinical approach, are particularly valuable reflective material because they demonstrate intellectual honesty and learning rather than self-congratulation.
MDT case + outcome letter
If the MDT resulted in a treatment decision that you subsequently communicated to the patient or to a referring team, the outcome letter is the documentary evidence of that communication. An annotated clinic letter describing the post-MDT consultation with the patient pairs naturally with the MDT case entry to create a full arc from decision to communication. This three-layer evidence structure - MDT entry, outcome letter, patient communication - is exactly what Domain 3 assessors look for in oncology applications.
Clinical trial participation
For Medical Oncology applicants in particular, clinical trial engagement documented through MDT evidence is a significant portfolio strand. If you routinely assess trial eligibility at MDT, refer patients for trial enrolment, serve as a principal or co-investigator, or have led trial-related discussions in MDT contexts, document this explicitly. The JRCPTB curriculum identifies research participation as a CiP strand, and MDT-linked trial evidence is a natural fit for demonstrating it. Research and publications evidence covers the broader framework, but the MDT is the specific clinical arena where trial evidence generation happens in oncology practice.
Common gaps assessors flag
Several patterns appear repeatedly in oncology Portfolio Pathway applications that result in additional evidence requests or adverse assessment outcomes. Most are avoidable with good documentation practice.
Volume without quality. A log of 80 MDT meetings with no case-level annotation tells the assessor nothing about the clinical content of those meetings. Assessors do not count meetings; they read evidence of clinical reasoning.
Single tumour site dominance. If all annotated MDT evidence is from one tumour site and your SSG indicates broader caseload expectations, this will be flagged. Clinical Oncologists covering multiple disease sites are expected to reflect that breadth.
No Domain 2 or Domain 4 entries. If every MDT entry maps to Domains 1 and 3 only, the portfolio signals that your MDT contributions never involved safety challenges, ethical complexity, or patient-centred advocacy. This rarely reflects reality - it reflects documentation choices.
Missing the biomarker and trial strand (Medical Oncology). JRCPTB assessors expect to see evidence that applicants are practising contemporary Medical Oncology, which means engaging with molecular profiling results, biomarker-driven treatment selection, and trial eligibility at the MDT. Portfolios built entirely around chemotherapy protocols from five or more years ago without any biomarker-era evidence create doubt about currency of practice.
No post-MDT communication evidence. If MDT entries document the decision but not the communication of that decision to the patient, a gap appears between the clinical decision-making strand and the patient communication strand. The outcome letter, or a note of the post-MDT consultation, closes this gap.
The directly-from-overseas applicant gap
For oncologists applying from outside the NHS, the MDT evidence gap is structural rather than documentary. If you have not worked in an NHS oncology department, you will not have NHS cancer MDT records. Assessors are aware of this and are not inflexible - but they need substantial contextual explanation and equivalent evidence to proceed. Tumour board records from a comparable system, annotated to map against NHS MDT standards, and supported by a contextual statement from an NHS educational supervisor (if one has been arranged), is the most viable approach. This is discussed further in the overview articles for Clinical Oncology and Medical Oncology.
All 18 specialisms
MDT participation is a relevant evidence strand across many specialisms, not just oncology. Cardiology, respiratory medicine, neurology, and most procedurally-complex specialisms have their own MDT evidence expectations. The guides below cover each of the 18 Portfolio Pathway specialisms in detail.
Sources
| Source | Publisher | Notes |
|---|---|---|
| Portfolio Pathway overview | GMC | The primary GMC guidance page for the Portfolio Pathway. Updated as the process evolves. |
| Good Medical Practice | GMC | The four-domain framework that structures all Portfolio Pathway evidence assessment. |
| Clinical Oncology Curriculum | Royal College of Radiologists | The RCR curriculum document that defines CiPs for Clinical Oncology, including MDT participation requirements. |
| Medical Oncology specialty page | JRCPTB | JRCPTB information on the Medical Oncology Portfolio Pathway route, including SCE requirements. |
| National Cancer Plan and strategy | NHS England | NHS England cancer strategy and service standards, including MDT requirements for cancer diagnosis and treatment planning. |
| Suspected cancer: recognition and referral (NG12) | NICE | NICE guideline establishing the two-week wait referral pathway and the clinical context in which oncology MDTs receive cases. |
| Clinical Oncology workforce guidance | Royal College of Radiologists | RCR guidance on Clinical Oncology service structure and the role of the clinical oncologist in the cancer MDT. |
| Generic Professional Capabilities framework | GMC | The GPC framework that underpins the generic curriculum strand common to all Portfolio Pathway specialisms. |
| Multidisciplinary teams in cancer care | Cancer Research UK | Background information on NHS cancer MDT structure, membership, and function. Not a primary regulatory source but useful context. |
| MDT workload and contracts guidance | BMA | BMA guidance on MDT participation in job plans, relevant for applicants documenting that MDT attendance was a formal part of their contracted clinical role. |
Frequently asked questions
How much MDT evidence is enough for a Clinical or Medical Oncology Portfolio Pathway application?
Neither the RCR nor the JRCPTB specifies a single MDT attendance number that automatically satisfies the evidence requirement. The working expectation across both pathways is that your MDT evidence should reflect sustained, active participation across a representative period - typically demonstrating regular attendance over at least 12 to 18 months, with evidence of case presentation, clinical decision-making contributions, and where possible a coordinator or chair role. Quality consistently outweighs count: a portfolio that documents 20 MDT attendances with case-level annotation and treatment decision rationale will carry more weight than a log of 80 meetings with no clinical commentary. Read your specific SSG - the RCR Clinical Oncology guidance and the JRCPTB Medical Oncology curriculum both address what assessors expect to see in the MDT evidence strand, and the language has evolved with recent curriculum updates.
What is the difference between MDT evidence requirements for Clinical Oncology and Medical Oncology?
The two specialties have different regulatory bodies and assessment frameworks. Clinical Oncology is assessed by the Royal College of Radiologists (RCR), whose Portfolio Pathway process centres on the Clinical Oncology Curriculum and the Capabilities in Practice (CiPs) mapped to that curriculum. The RCR expects evidence of MDT participation that demonstrates both radiotherapy planning expertise and systemic treatment decision-making, reflecting the dual-modality nature of the specialty. Medical Oncology is assessed via the JRCPTB route, which uses the Generic and Specialty Curricula and requires the MRCP(UK) SCE in Medical Oncology alongside the portfolio. The JRCPTB assessment team expects evidence of MDT contributions that demonstrate systematic treatment planning, clinical trial eligibility assessment, and complex case management. Both routes use the GMC's four-domain framework as their evidence scaffold, but the specific CiPs they assess against differ. Read both SSGs carefully before designing your MDT evidence strategy if there is any chance you are eligible for one pathway rather than the other.
Can virtual or remote MDT participation count as evidence?
Yes. Remote MDT participation became standard across many NHS oncology units during the pandemic and has remained a permanent feature of many services. Participation via video link, Teams, or similar platform counts in the same way as in-person attendance, provided you were actively contributing - not just logged on in the background. The documentation principles are identical: record the meeting, your role, the cases where you contributed, and the clinical decisions where your input was material. If your service moved to a hybrid or fully virtual model, include a brief contextual note when logging evidence, so assessors understand the service configuration rather than inferring you were not physically present. NHS England and NHSE guidance on cancer MDT standards does not distinguish between in-person and virtual participation in terms of the requirements it places on case review.
Do I need to evidence both MDT attendance and MDT chairing to have a complete oncology portfolio?
Chairing evidence strengthens a portfolio significantly but is not strictly mandatory for a complete application. The evidence requirement is for active MDT participation, which includes presenting cases, contributing to treatment decisions, and demonstrating that your input shapes clinical outcomes - chairing is one expression of this, but a strong presenter and clinical decision-maker who has never formally chaired can still build a convincing MDT evidence strand. That said, if you have chaired MDT meetings - whether as a regular chair, a covering chair, or a case-by-case chair for particularly complex patients - document that clearly and explicitly, because it moves your role from participant to clinical leader and maps directly to the leadership strand of Domain 1 and to Domain 3. The JRCPTB Medical Oncology curriculum specifically references leadership in MDT contexts as a CiP. If your clinical post does not include chairing, focus on demonstrating that your case presentations and treatment decision contributions are consistently at consultant level in terms of depth and complexity.
How should I handle patient confidentiality when including MDT records in my portfolio?
The same anonymisation principles that apply to clinic letters apply to MDT records. Patient name, date of birth, NHS number, hospital number, and any other direct identifiers must be removed or replaced before any MDT documentation is included in a Portfolio Pathway submission. For MDT meeting minutes or logs that include lists of patient names and diagnosis, you will need to redact all patient-identifiable fields, keeping only the case details that are clinically evidential. If you are including an annotated MDT case entry as a portfolio exhibit, the exhibit should be the anonymised case record plus your annotation, not the raw MDT proforma. Tumour-site MDTs often generate structured records (for example the Systemic Anti-Cancer Therapy or SACT data forms, or MDT outcome records fed into the Cancer Outcomes and Services Dataset) - these typically include patient identifiers and require careful redaction. Check your trust's Caldicott Guardian and information governance team guidance on portfolio submissions if you are unsure about the redaction standard expected at your institution.
What if I practise in a country where cancer MDTs are not structured the same way as in the NHS?
This is a material challenge for internationally-trained oncologists applying via the Portfolio Pathway. NHS cancer MDT standards are defined by NHS England and the National Cancer Plan, and the UK MDT model - with its structured meeting format, core membership requirements, and multidisciplinary decision record - is not universal. If your experience is from a healthcare system where multidisciplinary decision-making is informal, or where the formal MDT as defined by NHS standards does not exist, assessors will need substantial contextual explanation. The practical implication is that you should obtain a UK NHS post before applying, if at all possible. From within a UK clinical role, you can generate MDT evidence that maps directly to NHS standards. If a direct application from overseas is genuinely necessary, work with your educational supervisor to produce a detailed contextual statement explaining how decision-making in your system relates to NHS MDT practice, and supplement this with any equivalent formal tumour board or multidisciplinary conference evidence you have. Direct applications without UK MDT evidence face significant additional scrutiny and additional evidence requests are common - see the article on handling additional evidence requests for how to prepare.